Home › Pheochromocytoma › Illinois › Chicago
Pheochromocytoma clinical trials in Chicago, IL
3 studies for Pheochromocytoma are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
RecruitingPhase 2
- Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130), Chicago
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
RecruitingPhase 1/2
- The University of Chicago, Chicago
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- Lurie Children's Hospital-Chicago, Chicago
- Northwestern University, Chicago
- University of Illinois, Chicago
- and 1 more
About Pheochromocytoma
Pheochromocytoma is a rare tumor. Pheochromocytomas often cause the adrenal gland to make too many hormones. This can lead to high blood pressure.
More about Pheochromocytoma on MedlinePlus
Pheochromocytoma trials in other cities
- Washington, DC9 studies
- Philadelphia, PA3 studies
- Los Angeles, CA3 studies
- Nashville, TN3 studies
- Cedar Rapids, IA3 studies
- Baltimore, MD3 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.